Corpus overview


Overview

MeSH Disease

Human Phenotype

Angioedema (3)

Edema (1)

Hypoxemia (1)


Transmission

gender (2)


Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study

    Authors: Eli Mansour; Andre C Palma; Raisa G Ulaf; Luciana C Ribeiro; Ana Flavia Bernardes; Thyago A Nunes; Marcus V Agrela; Bruna Bombassaro; Milena Monfort-Pires; Rafael L Camargo; Eliana P Araujo; Natalia S Brunetti; Alessandro S Farias; Antonio L Falcao; Thiago M Santos; Plinio Trabasso; Rachel P Dertkigil; Sergio S Dertkigil; Maria Luiza Moretti; Licio A Velloso

    doi:10.1101/2020.08.11.20167353 Date: 2020-08-14 Source: medRxiv

    Coronavirus disease-19 (COVID-19) can develop into a severe respiratory syndrome MESHD that results in up to 40% mortality. Acute lung inflammatory edema HP edema MESHD is a major pathological finding in autopsies explaining O2 diffusion failure and hypoxemia HP hypoxemia MESHD. Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation MESHD in disease severity. SARS-CoV-2 enters cells employing angiotensin converting enzyme 2 (ACE2) as a receptor, which is highly expressed in lung alveolar MESHD cells. ACE2 is one of the components of the cellular machinery that inactivates the potent inflammatory agent bradykinin, and SARS-CoV-2 infection MESHD could interfere with the catalytic activity of ACE2, leading to accumulation of bradykinin. In this open-label, randomized clinical trial, we tested two pharmacological inhibitors of the kinin-kallikrein system that are currently approved for the treatment of hereditary angioedema MESHD angioedema HP, icatibant and inhibitor of C1 esterase/kallikrein, in a group of 30 patients with severe COVID-19. Neither icatibant nor inhibitor of C1 esterase/kallikrein resulted in significant changes in disease mortality and time to clinical improvement. However, both compounds promoted significant improvement of lung computed tomography scores and increased blood SERO eosinophils, which has been reported as an indicator of disease recovery. In this small cohort, we found evidence for a beneficial role of pharmacological inhibition of the kinin-kallikrein system in two markers that indicate improved disease recovery.

    A case report of COVID-19 virus infection MESHD in a patient with hereditary angioedema MESHD angioedema HP

    Authors: Amin Kanani

    doi:10.21203/rs.3.rs-41261/v1 Date: 2020-07-12 Source: ResearchSquare

    Background: This is the first reported case of coronavirus disease of 2019 (COVID-19) in a patient with hereditary angioedema MESHD angioedema HP ( HAE MESHD) type 1/2. Case presentation: A female TRANS with HAE MESHD receiving C1 inhibitor prophylaxis had no angioedema HP angioedema MESHD attacks when contracting the COVID-19 virus and had a mild clinical course.Conclusions: In this case there was no exacerbation of angioedema HP angioedema MESHD with the COVID-19 virus and the mild clinical course could possibly be from receiving C1 inhibitor prophylaxis.

    A case report of COVID-19 virus infection MESHD in a patient with hereditary angioedema MESHD angioedema HP

    Authors: Amin S. Kanani

    doi:10.21203/rs.3.rs-40931/v1 Date: 2020-07-10 Source: ResearchSquare

    Background: This is the first reported case of coronavirus disease of 2019 (COVID-19) in a patient with hereditary angioedema MESHD angioedema HP ( HAE MESHD) type 1/2. Case presentation: A female TRANS with HAE MESHD receiving C1 inhibitor prophylaxis had no angioedema HP angioedema MESHD attacks when contracting the COVID-19 virus and had a mild clinical course.Conclusions: In this case there was no exacerbation of angioedema HP angioedema MESHD with the COVID-19 virus and the mild clinical course could possibly be from receiving C1 inhibitor prophylaxis.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.